Why Pancreatic Cancer Matters
When most people think about cancer, they think about breast cancer, lung cancer or colon cancer. Far fewer people think about pancreatic cancer. Yet as oncologists caring for patients throughout Central Kentucky, pancreatic cancer is one of the diagnoses we worry about the most. Not because it is the most common cancer we see, but because it is often one of the most difficult to treat.
Unlike some cancers that can be found through routine screening, pancreatic cancer frequently develops without obvious warning signs. Patients often tell us they simply did not feel right. Maybe they lost weight without trying. Maybe they had persistent abdominal discomfort, back pain or digestive issues. Sometimes they were diagnosed with diabetes later in life and did not think much of it. Unfortunately, by the time symptoms become noticeable, the cancer has often already advanced.
Sobering Numbers
According to the American Cancer Society, more than 67,000 Americans are expected to be diagnosed with pancreatic cancer this year. More than 52,000 people will die from the disease. Despite advances in cancer treatment overall, pancreatic cancer remains one of the leading causes of cancer-related deaths in the United States.
Here in Kentucky, the challenge is even greater. Tobacco use, obesity, and diabetes, risk factors that are more common in Kentucky than in many other states, also increase the risk of pancreatic cancer. In many ways, pancreatic cancer reflects some of the broader health challenges our region has been working to address for years.
The Difficulty of Early Detection
One of the frustrations surrounding pancreatic cancer is that there is no simple screening test for the general population. That means awareness becomes incredibly important. We encourage people to pay attention to changes in their health. Unexplained weight loss, yellowing of the skin or eyes, persistent abdominal or back pain, loss of appetite, and new-onset diabetes can all warrant a conversation with a healthcare provider. These symptoms do not automatically mean cancer, but they should not be ignored.
Hope from a New Drug
Last week, researchers presented encouraging results from a major international clinical trial studying a new oral medication called daraxonrasib. The drug targets KRAS mutations, which are present in the vast majority of pancreatic cancers. Patients who received the medication after previous treatments had stopped working lived substantially longer than those who received standard treatment alone. Researchers also reported improvements in quality of life and fewer serious side effects.
It is important to keep expectations realistic. The medication is still under review and is not yet widely available. It is not a cure. But for a disease where meaningful progress has historically been difficult to achieve, these findings represent genuine hope.
Toward Personalized Care
Cancer care today looks very different from what it did even a decade ago. Genetic testing, precision medicine, and targeted therapies are helping us better understand which treatments may work best for individual patients. We are moving away from a one-size-fits-all approach and toward more personalized care. Pancreatic cancer remains one of the toughest cancers we treat. But it is no longer a disease without hope.
Our message is simple: know your risk factors, pay attention to your body, and do not delay seeking care when something feels wrong. Earlier diagnosis can make a difference. Continued research is making a difference. And for the first time in a long time, we are seeing signs that, even against pancreatic cancer, the future may be brighter than the past.